In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zocor 80 Mg Dose Remains Appropriate Option, FDA And Merck Agree

This article was originally published in The Pink Sheet Daily

Executive Summary

JAMA editorial suggests that 80 mg Zocor dose should be used with caution, given rate of myopathy reported in "A to Z" trial. FDA and Merck both feel that current Zocor labeling appropriately describes dosing options.

You may also be interested in...



Keytruda And FDA’s Oncology Center of Excellence: The Regulatory Milestones Keep Coming

Merck’s anti-PD-1 therapy Keytruda keeps piling up new indications, including three approved by US FDA in just two weeks – all during a pandemic. The remarkable therapy has been a centerpiece for an equally remarkable period of regulatory innovation.

US FDA Stays Out Of Hot Seat On COVID-19 Response – So Far

Commissioner Stephen Hahn was largely spared any direct criticism during a very long House hearing on COVID-19 response activities. That is a promising sign for the agency.

What Is A ‘Line Extension’? Medicaid Tries Again With Sweeping Definition

In the latest reminder of how badly industry lost the argument over the value of incremental improvements in formulations, US is proposing enhanced Medicaid rebates on virtually all new formulations of existing brands.

Topics

UsernamePublicRestriction

Register

LL082593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel